Last reviewed · How we verify
Itami
Itami is a Small molecule drug developed by Fidia Farmaceutici s.p.a.. It is currently FDA-approved. Also known as: Diclofenac sodium 140 mg medicated plaster.
At a glance
| Generic name | Itami |
|---|---|
| Also known as | Diclofenac sodium 140 mg medicated plaster |
| Sponsor | Fidia Farmaceutici s.p.a. |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Itami CI brief — competitive landscape report
- Itami updates RSS · CI watch RSS
- Fidia Farmaceutici s.p.a. portfolio CI
Frequently asked questions about Itami
What is Itami?
Itami is a Small molecule drug developed by Fidia Farmaceutici s.p.a..
Who makes Itami?
Itami is developed and marketed by Fidia Farmaceutici s.p.a. (see full Fidia Farmaceutici s.p.a. pipeline at /company/fidia-farmaceutici-s-p-a).
Is Itami also known as anything else?
Itami is also known as Diclofenac sodium 140 mg medicated plaster.
What development phase is Itami in?
Itami is FDA-approved (marketed).
Related
- Manufacturer: Fidia Farmaceutici s.p.a. — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Diclofenac sodium 140 mg medicated plaster
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing